Results 131 to 140 of about 21,053 (285)

Effectiveness of direct oral anticoagulants for all‐cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
This study shows that overweight and obese patients with atrial fibrillation experience improved outcomes when treated with DOACs compared with VKAs. Specifically, DOAC use was associated with lower risks of all‐cause mortality and cardiovascular events.
Danilo Menichelli, Gianluca Gazzaniga, Emilia Antonucci, Gualtiero Palareti, Daniela Poli, Pasquale Pignatelli, Daniele Pastori, the START2 Register Investigators, Benilde Cosmi, Daniela Poli, Elena Lotti, Martina Berteotti, Walter Ageno, Giovanna Colombo, Salvatore Bradamante, Eugenio Bucherini, Monica Vastola, Paola Casasco, Antonio Chistolini, Alessandra Serrao, Luciano Crippa Ambulatorio Emostasi, Raimondo De Cristofaro, Erica De Candia, Valeria De Micheli, Marcello Di Nisio, Anna Falanga, Teresa Lerede, Elvira Grandone, Donatella Colaizzo, Antonio Insana, Nicola Lucio Liberato, Domenico Lione, Rosa Maria Lombardi, Giacomo Lucarelli, Giuseppe Malcangi, Catello Mangione, Giuliana Martini Centro Emostasi, Marco Marzolo, Giovanni Nante, Vincenzo Oriana, Paolo Pedico, Simona Pedrini, Vittorio Pengo, Antonietta Piana, Francesco Cibecchini, Simona Pezzella, Pasquale Pignatelli, Daniele Pastori, Vincenza Rossi, Lucia Ruocco, Paolo Chiarugi, Serena Rupoli, Domizio Serra, Carmine Spataro, Margherita Reduzzi, Sophie Testa, Oriana Paoletti, Vincenzo Toschi, Claudio Vasselli   +58 more
wiley   +1 more source

Edoxaban pharmacokinetics during in vitro continuous renal replacement therapy

BMC Nephrology
Background To evaluate the clearance of edoxaban during modeled in vitro continuous renal replacement therapy (CRRT), assess protein binding and circuit adsorption, and provide initial dosing recommendations.
Eric Wenzler, Kaitlyn Dalton, Lauren Andrews, Scott T. Benken   +3 more
doaj   +1 more source

Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy

ESC Heart Failure, 2019
Extensive data support the safety of direct oral anticoagulants compared with vitamin K antagonists in patients with non‐valvular atrial fibrillation, leading to a significantly increase in the use of these compounds in clinical practice.
Mattia Galli, Domenico D'Amario, Felicita Andreotti, Italo Porto, Rocco Vergallo, Mario Sabatelli, Stefano Lancellotti, Emiliana Meleo, Raimondo De Cristofaro, Filippo Crea   +9 more
doaj   +1 more source

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundWe studied the concomitant use of single antiplatelet therapy (SAPT) on the efficacy and safety of the anti‐Xa agent edoxaban in patients with atrial fibrillation (AF). Methods and ResultsENGAGE AF‐TIMI 48 was a randomized trial that compared 2
Haiyan Xu, Christian T. Ruff, Robert P. Giugliano, Sabina A. Murphy, Francesco Nordio, Indravadan Patel, Minggao Shi, Michele Mercuri, Elliott M. Antman, Eugene Braunwald   +9 more
doaj   +1 more source

Efficacy and Safety of Edoxaban in Cancer-Associated Venous Thromboembolism: A Real World Retrospective Study [PDF]

, 2022
Elisa Grifoni, Andrea Baroncelli, Gabriele Pinto, Eleonora Cosentino, Irene Micheletti, Ira Signorini, Grazia Panigada, Giancarlo Landini, Luca Masotti   +8 more
openalex   +1 more source

Anticoagulants for acute ischaemic stroke [PDF]

, 2015
Peer reviewedPublisher ...
Counsell, Carl, Kane, Edward J, Sandercock, Peter A G   +2 more
core   +1 more source

IQWiG bestätigt beträchtlichen Zusatznutzen für Edoxaban [PDF]

, 2015
ред
openalex   +1 more source

Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. [PDF]

, 2018
Patients with chronic kidney disease (CKD) are predisposed to heart rhythm disorders, including atrial fibrillation (AF)/atrial flutter, supraventricular tachycardias, ventricular arrhythmias, and sudden cardiac death (SCD).
Amann, Kerstin, Banerjee, Debasish, Bansal, Nisha, Blankestijn, Peter J, Boriani, Giuseppe, Bunch, Jared, Carrero, Juan-Jesus, Chan, Christopher T, Charytan, David M, Cheung, Michael, Clase, Catherine M, Conen, David, Conference Participants, Deo, Rajat, Friedman, Allon N, Genovesi, Simonetta, Herzog, Charles A, Holden, Rachel M, House, Andrew A, Jadoul, Michel, Jardine, Alan G, Johnson, David W, Jun, Min, Kasner, Scott E, Labriola, Laura, Mark, Patrick B, McCullough, Peter A, Nolin, Thomas D, Passman, Rod S, Pecoits-Filho, Roberto, Potpara, Tatjana S, Pun, Patrick H, Reinecke, Holger, Ribeiro, Antonio L P, Rossignol, Patrick, Shen, Jenny I, Shroff, Gautam R, Sood, Manish M, Tsukamoto, Yusuke, Turakhia, Mintu P, Wang, Angela Yee-Moon, Wanner, Christoph, Weir, Matthew R, Wetmore, James B, Wheeler, David C, Winkelmayer, Wolfgang C, Wranicz, Jerzy K, Yamasaki, Hiro, Zareba, Wojciech   +48 more
core   +3 more sources

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study [PDF]

, 2018
Alexander T. Cohen, Cihan Ay, Pierre Hainaut, Hervé Decousus, Ulrich Hoffmann, Seán Gaine, Michiel Coppens, Pedro Silva Cunha, David Jiménez, Beatrice Amann‐Vesti, Bernd Brüggenjürgen, Pierre Lévy, Julio López Bastida, Éric Vicaut, Petra Laeis, Eva‐Maria Fronk, Wolfgang Zierhut, Thomas Malzer, Peter Bramlage, Giancarlo Agnelli, Giancarlo Agnelli   +20 more
openalex   +1 more source

Population pharmacokinetics and pharmacodynamics of edoxaban in pediatric patients

CPT: Pharmacometrics & Systems Pharmacology
Edoxaban is an orally active inhibitor of activated factor X (FXa). Population pharmacokinetic (PK) and pharmacodynamic (PD) analyses were performed to characterize the PK and PK–PD relationships of edoxaban in pediatric patients to identify the ...
Peng Zou, Akhilesh Atluri, Peter Chang, Michael Goedecke, Tarek A. Leil   +4 more
doaj   +1 more source